Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of GSK5533524 in Advanced Solid Tumors
jRCT2031250763Phase 1Recruiting
- Sponsor
- GSK
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of GSK5533524 in Nonhematologic neoplasms (2 arms), sponsored by GSK. Primary endpoints: Incidence of dose-limiting toxicities per dose level (Part 1a), Incidence and severity of adverse events and serious adverse events per dose level (Part 1a) and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
GSK5533524
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031250763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250763.